Journal
BONE
Volume 140, Issue -, Pages -Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bone.2020.115563
Keywords
Adolescent idiopathic scoliosis; Biomarkers; GWAS; Epigenetics; DNA methylation; Noncoding RNAs
Categories
Funding
- EuroSpine Society
- Fundacion Ramon Areces [OTR2019-19499INVES/VINA RIBES]
- Ministerio de Economia y Competitividad, Instituto de Salud Carlos III (Spain) through CIBERer (Biomedical Network Research Centre for Rare Diseases)
- Ministerio de Economia y Competitividad, Instituto de Salud Carlos III (Spain) through CIBERer (INGENIO2010)
- Generalitat Valenciana (Spain) [PROMETEO/2018/135]
- Ministerio de Ciencia e Innovacion (Spain) through the Competitiveness Programme for the Promotion of Talent and its Employability in R+ D+ I Torres Quevedo [PTQ-15-07899]
- Programme PhD training in companies of the Ministerio de Economia, Industria y Competitividad (Spain) [DI-16-08917]
Ask authors/readers for more resources
Scoliosis is defined as the three-dimensional (3D) structural deformity of the spine with a radiological lateral Cobb angle (a measure of spinal curvature) of >= 10 degrees that can be caused by congenital, developmental or de- generative problems. However, those cases whose etiology is still unknown, and affect healthy children and adolescents during growth, are the commonest form of spinal deformity, known as adolescent idiopathic scoliosis (AIS). In AIS management, early diagnosis and the accurate prediction of curve progression are most important because they can decrease negative long-term effects of AIS treatment, such as unnecessary bracing, frequent exposure to radiation, as well as saving the high costs of AIS treatment. Despite efforts made to identify a method or technique capable of predicting AIS progression, this challenge still remains unresolved. Genetics and epigenetics, and the application of machine learning and artificial intelligence technologies, open up new avenues to not only clarify AIS etiology, but to also identify potential biomarkers that can substantially improve the clinical management of these patients. This review presents the most relevant biomarkers to help explain the etiopathogenesis of AIS and provide new potential biomarkers to be validated in large clinical trials so they can be finally implemented into clinical settings.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available